Accelerate to discover

Back to filter

Related topics

Cardiomyocyte isolation using Cellenion’s cellenONE instrument

Cellenion

Mar 24, 2023

The cellenONE platform is ideal for the isolation of fragile and heterogeneous cell size populations, such as...

ACCELA educational webinar: Unlocking Spatial Biology with RareCyte Orion

RareCyte

Mar 16, 2023

Experience Spatial Biology with Orion Multiplex Imaging. Orion is a benchtop, high...

Recorded webinar: Anesthesia Considerations in Small Animal Imaging

Spectral Instruments Imaging

Mar 13, 2023

Anesthesia settings and operation of Optical Imaging Systems: methods, animal handling, safety and regulatory...

Introducing Cytek Human Leukocyte Kit, the first ever 15-color lyse no-wash assay

Cytek Biosciences

Mar 13, 2023

This kit has been designed to enumerate all major leukocyte subsets and it mirrors and expands on those identified in a...

Mar 25, 2023

Immunofluorescence Imaging for Rare Cell Detection with CyteFinder II

RareCyte

Mar 7, 2023

CyteFinder II Instruments are high speed, whole slide imaging systems with options for liquid biopsy analysis and...

NanoCellect Webinar: Optimizing the Cell Line Development Process with Microfluidic Cell Sorting

NanoCellect

Mar 3, 2023

Single-cell selection and cloning are required for bioengineering workflows such as antibody production, cell therapy,...

New Kit for Bacterial analysis expands capability of Guava Muse flow cytometer

Luminex

Feb 20, 2023

With the Guava Muse cell analyzer, you can now achieve highly quantitative results at a fraction of the price, effort,...

Mar 25, 2023

Flash news - did you know, that you can use Singulator S100 also for plant research?

S2 Genomics

Feb 10, 2023

In this short TechNote you can find how Singulator can help the data quality in Single cell sequencing - now even in...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey